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Abstract 
Background: As an important bulk chemical for synthetic rubber, isoprene can be biosynthesized by robust 
microbes. But rational engineering and optimization are often demanded to make the in vivo process feasible due 
to the complexities of cellular metabolism. Alternative synthetic biochemistry strategies are in fast development to 
produce isoprene or isoprenoids in vitro.
Results: This study set up an in vitro enzyme synthetic chemistry process using 5 enzymes in the lower mevalonate 
pathway to produce isoprene from mevalonate. We found the level and ratio of individual enzymes would signifi-
cantly affect the efficiency of the whole system. The optimized process using 10 balanced enzyme unites (5.0 µM 
of MVK, PMK, MVD; 10.0 µM of IDI, 80.0 µM of ISPS) could produce 6323.5 µmol/L/h (430 mg/L/h) isoprene in a 2 ml 
in vitro system. In a scale up process (50 ml) only using 1 balanced enzyme unit (0.5 µM of MVK, PMK, MVD; 1.0 µM of 
IDI, 8.0 µM of ISPS), the system could produce 302 mg/L isoprene in 40 h, which showed higher production rate and 
longer reaction phase with comparison of the in vivo control.
Conclusions: By optimizing the enzyme levels of lower MVA pathway, synthetic biochemistry methods could be set 
up for the enzymatic production of isoprene or isoprenoids from mevalonate.
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Background
Commodity chemicals are traditionally produced from 
petroleum via the energy-intensive chemical methods. 
Alternative process that does not rely on the petroleum 
resources and chemo-process is under fast development 
for chemical production, using the advanced tools of syn-
thetic biology and metabolic engineering [1, 2]. Recently, 
isoprene and a variety of isoprenoids can be produced 
from renewable feedstock through engineered microbes 
[3–7]. The general strategy is engineering the whole 
isoprenoid biosynthesis pathways in the chassis strains 
[6], and the mevalonate (MVA) pathway other than the 
methylerythritol 4-phosphate (MEP) pathway is usually 
selected to construct robust strains with higher produc-
tion titers [8].
However, the biosynthesis of isoprene and isoprenoids 
by the cell-based strategy faced one major bottleneck: the 
nutrient limitation and the accumulation of toxic inter-
mediates or products may lead to cell growth inhibition 
and limited yields and titers; thus rational engineering 
and optimization are often demanded to make the pro-
cess economically feasible [9–12]. Corresponding syn-
thetic biochemistry tool has also been demonstrated to 
overcome the major bottleneck of the cell-based strategy, 
especially in rational optimization of synthetic multi-
enzyme pathways [13]. The emergence of cell-free sys-
tem has several advantages over the cell-base system: (1) 
process can be operated continuously; (2) can synthesize 
hazard products which are toxic towards living cell sys-
tem; (3) enzyme can be quantitatively and biochemically 
adjusted to optimize flux through the metabolic path-
ways; (4) reduce the operation (like gas-stripping) and 
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purification requirements; (5) higher yields without com-
peting cellular pathways. In case of isoprene biosynthesis, 
a recent cell-free approach for the conversion of the glyc-
olysis intermediate phosphoenolpyruvate into isoprene at 
nearly 100% molar yield was promoted [14]. The in vitro 
system involves enzymes through the full MVA pathway. 
While challenges also exist for the synthetic biochemistry 
platform, as the cofactors of ATP, NADPH, and acetyl-
CoA need to be balanced in the complex MVA pathway: 
NADPH and acetyl-CoA are involved in the upper MVA 
pathway (from pyruvate to MVA), ATP is involved in the 
lower MVA pathway (from MVA to isoprene). Thus addi-
tional enzymes are needed to balance the supply/con-
sumption of these co-factors which increased the total 
enzymes of 12 in the complex in vitro system for bioiso-
prene [13, 14].
This study focused on implementing an enzymatic 
process only consisting of lower MVA pathway for the 
biosynthesis of isoprene directly from MVA. In the dem-
onstrated system, the cofactors of NADPH and acetyl-
CoA are not involved, which decreases the needs of 
additional enzymes to balance these factors. Moreover, 
the enzyme activities and quantities of the simplified sys-
tem (only involves 5 enzymes) can be easily and precisely 
adjusted to optimize flux through the biochemical steps, 
which would improve the conversion efficiency compar-
ing to the current in vitro platform for bioisoprene.
Results and discussion
Purification of the enzymes in lower MVA pathway
In this study, four biosynthetic enzymes of lower MVA 
pathway and isoprene synthase were individually pre-
pared by recombinant E. coli strains (Table 1) and puri-
fied before in  vitro production. Through these enzymes 
mevalonate can be converted to dimethylallyl pyrophos-
phate (DMAPP) by primary mevalonate kinase (MVK, 
EC 2.7.1.36) and secondary phosphorylation (phos-
phomevalonate kinase, PMK, EC 2.7.4.2), decarboxyla-
tion (diphosphomevalonaet decarboxylase, MVD, EC 
4.1.1.33) and isomerization (isopentenyl diphosphate 
isomerase, IDI, EC 5.3.3.2), then the isoprene synthase 
(ISPS, EC 4.2.3.27) catalyzes the formation of isoprene 
from DMAPP. For each molecular of isoprene from 
MVA, 3 ATP is needed and NADPH is not demanded 
for the in vitro bioconversion, which is different with the 
in  vivo system from pyruvate [14, 15]. In order to pre-
vent the formation of inclusion body and ensure correct 
enzyme folding, each enzyme was purified and checked 
Table 1 Bacterial strains and plasmids used in this study
Strain/plasmid/primer Relevant genotype/property/sequence Source/reference
Strains
 E. coli BL21(DE3) F−ompThsdSB(rB
−mB
−) gal dcm rne131 (DE3) Invitrogen
 MVK producer BL21(DE3)/pET-ERG12 This study
 MVD producer BL21(DE3)/pET-ERG8 This study
 PMK producer BL21(DE3)/pET-ERG19 This study
 IDI producer BL21(DE3)/pET-IDI This study
 ISPS producer BL21(DE3)/pET-ISPS This study
Plasmids
 pYJM14 pTrcHis2B derivative carryinggenes ERG8, ERG12, ERG19 and IDI, Trc promoter, ApR [16]
 pET-ERG12 pET30a(+) derivative carryinggenes gene ERG12, T7 promoter, KanR This study
 pET-ERG8 pET30a(+) derivative carryinggenes gene ERG8, T7 promoter, KanR This study
 pET-ERG19 pET30a(+) derivative carryinggenes geneERG19, T7 promoter, KanR This study
 pET-IDI pET30a(+) derivative carryinggenes gene IDI, T7 promoter, KanR This study
 pET-ISPS pET30a(+) derivative carryinggenes gene ISPS, T7 promoter, KanR This study









 IDI_R 5′- CCGCTCGAGTTATAGCATTCTATGAATTT-3′
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their molecular size by SDS-page before enzymatic assay 
experiments. We found that keeping the cultures at 20 °C 
after IPTG induction in the fermentation process helped 
to improve the yield of soluble recombinant enzymes. 
The purity and molecular size of the purified enzymes 
can be seen in Fig. 1.
In vitro production of isoprene from mevalonate
With the purified enzymes, we further tested whether 
the lower mevalonate pathway can be reconstituted 
in  vitro by mixing of substrate and ATP with the puri-
fied enzymes. The addition of ATP is compulsory as three 
ATP are used in the phosphorylation and decarboxy-
lation of mevalonate to IPP (Fig. 1). In the 2 ml in vitro 
system with purified enzymes (0.5  µM each), substrate 
(2.5 mM) and ATP (12 mM), we took samples and ana-
lyzed total isoprene at different time points and calculate 
the rate of reaction (total isoprene/L/h) at the different 
time points. The results showed that the maximum iso-
prene production (76.5 µmol/L/h, 5.2 mg/L/h) occurred 
at 4 h after the addition of ATP and mevalonate (Fig. 2a), 
similar with the time course curve of in  vitro isoprene 
production from PEP in the previous study [14].
We next tested the optimum mevalonate/ATP ratio in 
the 2 ml in vitro system. The optimum concentration of 
mevalonate (substrate) was analyzed by starting with a 
fixed amount of ATP (12 mM) and sequentially increas-
ing amount of mevalonate (Fig. 2b). The results showed 
that the maximum isoprene production was achieved 
when 2.5 mM mevalonate was added in the system, and 
the isoprene production was decreased when the initial 
concentration of mevalonate was over 2.5 mM. We also 
tested the optimum concentration of ATP with fixed 
amount of mevalonate (2.5  mM). The results showed 
that supplementation of 10  mM ATP resulted in the 
maximum isoprene production (Fig.  2c). The produc-
tion of isoprene was increasing with the increasing of 
ATP from 2 to 12  mM, it is suggested that the lower 
pathway of MVA was inhibited when the concentration 
of substrate of mevalonate was higher than 2.5 mM. The 
optimum ratio for substrate (mevalonate) and cofactors 
(ATP) is around 1:4, which is excess to the theoretical 
Fig. 1 The purified enzymes of the lower MVA pathway. a Pathway overview. The lower MVA pathway consists of 5 enzymatic reactions each cata-
lyzed by MVK (mevalonate kinase, EC 2.7.1.36), PMK (phoshpomevalonate kinase, EC 2.7.4.2), MVD (diphoshpomevalonate kinase, EC 4.1.1.33), IDI 
(isopentenyl diphosphate isomerase, EC 5.3.3.2) and ISPS (isoprene synthase, EC 4.2.3.27). b The size of the purified enzymes
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ATP consumption (1:3) in the lower mevalonate pathway 
(Fig. 1). The excess addition of ATP is similar with previ-
ous study when acetyl-CoA was utilized as substrate for 
the in vitro production of isoprene [14].
Quantitatively balancing enzyme levels to maximum the 
isoprene production
In the in vitro isoprene biosynthesis system, the enzyme 
quantity can be precisely adjusted to optimize the flux 
through the biochemical steps comparing with the iso-
prenoids biosynthesis using living cells, in which pro-
moter induction is often highly cooperative and fine 
control is difficult [11]. To quantitatively construct bal-
anced in  vitro system, we firstly screened the bottle-
neck enzymes which significantly affect the isoprene 
production. The effects of enzyme levels towards iso-
prene production were tested by varying the levels 
between 0.02 and 5 µM with the constant levels of other 
four enzymes at 0.5 µM (Fig. 3a) in the 2 ml in vitro sys-
tem. The results showed that the enzymes had differ-
ent effects towards the isoprene production. PMK and 
MVD were not belonging to the bottleneck enzymes in 
the pathway, as their levels did not significantly influence 
the isoprene production. For the enzymes of MVK and 
IDI, their increasing levels generated a 30–90% increase 
in isoprene production: MVK reached the maximum iso-
prene production at the level of 0.5 µM while IDI reached 
the maximum isoprene production at 1.0  µM (Fig.  3a). 
The last enzyme of ISPS, which catalyzes the production 
of isoprene from DMAPP, belonged to the bottleneck 
Fig. 2 Determination of the optimal enzymatic conditions. The production rate of isoprene in 2 ml enzymatic system under conditions: a 2.5 mM 
mevalonic acid, 12 mM ATP, with varied reaction time; b 12 mM ATP, reaction for 4 h, with varied concentration of mevalonic acid; c 2.5 mM meva-
lonic acid, reaction for 4 h, with varied concentration of ATP. The data shown are means of three repeated experiments and the error bars present 
the standard deviation
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enzyme of this in  vitro system, as its increasing levels 
from 0.02 to 5  µM gave a 30-fold increase in isoprene 
production. The results indicated that IDI and ISPS 
were two bottleneck enzymes in the in vitro production 
of isoprene from mevalonate, and their levels needed to 
be adjusted to balance the in vitro system. From the data 
of Fig.  1a, we could deduce that the optimized molar-
ity ratio of MVK: PMK: MVD: IDI: ISPS was 1:1:1:2:16. 
One such balanced synthetic unit (0.5 µM of MVK, PMK, 
MVD; 1.0 µM of IDI, 8.0 µM of ISPS) could produce up 
to 382.4 µmol/L/h (26 mg/L/h) isoprene, which is nearly 
five folds of the isoprene production by the unbalanced 
synthetic unit (0.5 µM of each enzyme, Fig. 3b). Moreo-
ver, when multiple synthetic unit is supplemented in the 
2 ml in vitro system, the production efficiency of isoprene 
could be significantly improved, 10 balanced synthetic 
units (5.0  µM of MVK, PMK, MVD; 10.0  µM of IDI, 
80.0 µM of ISPS) would increase the isoprene production 
to 6323.5 µmol/L/h (430 mg/L/h) (Fig. 3c).
Our results demonstrated that balancing of enzyme 
levels could significantly increase the in vitro production 
of isoprene, which followed the results of in  vivo stud-
ies that the balanced expression levels of heterologous 
enzymes is a key determinant in optimizing isoprenoid 
production [10, 11]. The in  vivo studies aim to balance 
the heterologous pathways to reduce the growth inhibi-
tion effects towards the microbial hosts while the in vitro 
studies more focus on overcoming the limiting biochemi-
cal steps in heterologous flux towards the objective prod-
ucts. For example, we have noted that the enzymes levels 
of MVK did not apparently affect the in vitro production 
of isoprene (Fig. 3a) and they were kept at minimum level 
Fig. 3 Optimization of the in vitro synthetic unit and the effects of enzyme levels on isoprene production. a Determination of the optimal enzyme 
level of each enzyme within synthetic unit, when four other enzymes were kept at constant level of 0.5 µM. b Production of isoprene using bal-
anced or unbalanced synthetic unit. c Effects of increased synthetic units towards the isoprene production. Each unbalanced synthetic unit has 
0.5 µM of MVK, PMK, MVD, IDI and ISPS. Each balanced synthetic unit has 0.5 µM of MVK, PMK, MVD; 1.0 µM of IDI, 8.0 µM of ISPS (MVK:PMK:MVD:I
DI:Isps = 1:1:1:2:12). a, b and c followed the below conditions: 50 mM phosphate buffer, 30 mM potassium chloride, 10 mM magnesium chloride, 
and 4 mM β-mercaptoethanol, 10 mM ATP and 2.5 mM mevalonic acid. The data shown are means of three repeated experiments and the error bars 
present the standard deviation
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(0.5  µM) in our balanced synthetic unit. While in the 
in vivo studies for isoprene [3, 16] and isoprenoids biosyn-
thesis [11], the expression of MVK were adjusted at higher 
levels, in which MVK was believed to be a key enzyme 
and was expressed by stronger promoters than PMK and 
MVD. We hypothesized that the in vivo system has spe-
cific mechanism to adjust the intra- and extracellular lev-
els of mevalonate (MVA), and higher level of MVK helps 
to convert the intracellular MVA before it is transported 
off the cell. The last enzyme ISPS were both found bottle-
neck enzyme in previous study [17] as well as in this study. 
From the data of this study, ISPS catalyzed the rate-limit-
ing biochemical step in heterologous flux from DMAPP 
to the isoprene. The in  vivo models also supported this 
conclusion, it was proved that lower expression level of 
key enzyme downstream the IPP/DMAPP will lead to the 
accumulation of C5 building blocks (IPP and DMAPP), 
and will inhibit normal cell growth [9].
Comparing with the previous in vitro experiment [14] 
which incorporated as much as 12 enzymes of upper and 
lower MVA pathways, this study demonstrated a sim-
pler system which only involved 5 enzymes and their 
levels were precisely adjusted to optimize flux through 
the biochemical steps. After optimization, the isoprene 
production was significantly improved (from 214.5 to 
6323.5  µmol/L/h) comparing with the previous in  vitro 
experiment [14].
In vitro and in vivo production of isoprene from MVA: a 
comparison
We further set up a 50 ml in vitro system and compared 
its isoprene production with the in vivo flask fermenta-
tion (50  ml), from the same starting concentration of 
mevalonate substrate. The results showed that the in vitro 
model apparently had higher isoprene production rate 
than the in vivo model during the earlier 12 h of isoprene 
production (Fig. 4). The initial isoprene production rate 
is about 220.6 µmol/L/h (15.0 mg/l/h, total 160 mg/l iso-
prene within 12 h), which is similar with the recent study 
for the in vitro isoprene production system [14]. Moreo-
ver, isoprene production remained longer for the in vitro 
system: from 20 to 40 h, the production of isoprene was 
suspended in the in  vivo system, but was consistent in 
the in  vitro system. Until 40  h, the production of iso-
prene from mevalonate by the in vitro system reached to 
4442.4 µmol/L (302.0 mg/l). From the comparison of the 
isoprene production by the in vitro and the in vivo mod-
els, we could deduce that the balanced in  vitro enzyme 
system led to higher production rate and prolonged iso-
prene production. We estimated that the unbalanced 
intracellular enzymes levels, accumulated toxic interme-
diates, competitive consumption of co-factors may affect 
the isoprene production by the in vivo methods.
Conclusion
In this study, isoprene was produced from mevalonate by 
an optimized enzymatic process using the five recombi-
nant enzymes of MVK, PMK, MVD, IDI and ISPS from 
the lower MVA pathway. Balancing and increasing the 
enzyme levels could apparently enhance isoprene pro-
duction, indicated that the production rate could be 
further increased by raising the concentrations of the 
mevalonate and enzymes, which is hard to achieved by 
the in vivo approaches. When the balanced enzyme units 
were increased to ten, the proposed process would pro-
duce 6323.5  µmol/L/h (430  mg/L/h in a 2  ml system) 
isoprene from mevalonate. Moreover, this study showed 
that the proposed process has the advantages of longer 
producing period of 40 h comparing with the controlled 
in vivo process. The improved production efficiency indi-
cated that the proposed strategy is useful for the enzy-
matic production of isoprene or isoprenoids.
Methods
Strains and plasmids
Bacterial strains and plasmids used in this study were 
listed in Table 1. Escherichia coli strain DH5α and BL21 
(DE3) and Saccharomyces cerevisiae used in this study 
were purchased from Invitrogen. The E. coli DH5α 
strain and E. coli BL21 (DE3) were used for plasmids 
Fig. 4 The comparison of isoprene production by 50 ml in vitro 
and in vivo systems. The concentration of MVK (0.5 µM) was similar 
in both in vitro (black) and in vivo (red) systems. The cell free in vitro 
system has 1 synthetic unit (0.5 µM of MVK, PMK, MVD; 1.0 µM of 
IDI, 8.0 µM of ISPS) with 50 mM phosphate buffer, 30 mM potassium 
chloride, 10 mM magnesium chloride, and 4 mM β-mercaptoethanol. 
50 ml culture of engineered E. coli (BL21(DE3)/pYJM14/pACY-ISPS, 
Table 1) which expressed the five enzymes of the lower MVA pathway 
was utilized as the in vivo control. Both systems was initiated by addi-
tion of 2.5 mM mevalonic acid and incubated at 30 °C in rotary shaker 
(180 rpm). Samples were taken to analyze their isoprene production 
at different time points. The data shown are means of three repeated 
experiments and the error bars present the standard deviation
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preparation and for protein overexpression respectively. 
S. cerevisiae was used for gene for cloning. E. coli DH5α 
and E. coli BL21 (DE3) were cultured in Luria–Bertani 
(LB) broth in construction of strains and plasmids. S. cer-
evisiae was cultured in YPD medium. Antibiotics were 
added at final concentration of 50 μg/mL for kanamycin, 
34 μg/mL for chloramphenicol and 100 μg/mL for ampi-
cillin when necessary.
Protein preparation and purification
All PCRs were done using PrimerSTAR Max DNA pol-
ymerase (TAKARA, Dalian, China). Four genes of the 
enzymes MVK, PMK, MVD, IDI were amplified from S. 
cerevisiae genome (obtained from ATCC201508D) and 
cloned into the plasmid pET-30a(+). The plasmid pET-
ERG12 was constructed by cloning the ERG12 gene (for 
MVK) of S. cerevisiae into HindIII and XhoI sites of vec-
tor pET-30a(+) with primers ERG12_F and ERG12_R. 
The plasmid pET-ERG8 was constructed by cloning the 
ERG8 gene (for PMK) from S. cerevisiae into EcoRI and 
XhoI sites of vector pET-30a(+) with primers ERG8_F 
and ERG8_R. The plasmid pET_ERG19 was constructed 
by cloning the ERG19 gene (for MVD) from S.cerevisiae 
into BamHI and XhoI sites of vector pET-30a(+) with 
primers ERG19_F and ERG19_R. The fourth gene for 
enzyme IDI was amplified by PCR using primers IDI_F 
and IDI_R and cloned into BamHI and XhoI sites of 
vector pET-30a(+). The resulting plasmid was named 
pET-IDI. The isoprene synthase (ISPS) from poplar was 
synthesized after code optimization and digested with 
enzymes BamHI and XhoI, then ligated into the pET-
30a(+), the resulting plasmid was named pET-ISPS 
(Table 1).
Individual recombinant enzymes were extracted 
and purified from the strains of E.coli BL21(DE3) har-
boring the relevant plasmids. The cultures were incu-
bated in 200  ml LB medium with 50  µg/ml Kanamycin 
at 37  °C until the OD600 reached 0.6–0.8. The cultures 
were added 0.2 mM IPTG for induction and were cooled 
to 20  °C for protein expression. After further growth at 
20  °C for 12 h, cells were harvested by centrifugation at 
8000g and suspended in 10 mL 50 mM phosphate buffer 
(pH7.4) containing 4  mM β-mercaptoethanol. The sus-
pension was lysed by sonication (at 60% output for 3  s 
pulses with 3 s intervals between each cycle) for 40 min 
at 4  °C with tube jacketed in wet ice and centrifuged 
at 18,000g for 10  min at 4  °C. The supernate filtered by 
0.22 µm PALL filter was added into the Nickel Column, 
which was washed by 10  ml water and 10  ml binding 
buffer in order to ensure that the column was equili-
brated, and then the protein containing 6 His-tag was 
able to specifically bind to nickel column. Unbound pro-
tein was washed out with 10  ml washing buffer 1, then 
washing Buffer 2 was used to wash any nonspecific bind-
ing protein. Elution buffer was added to wash the specific 
protein with collection of 10  ml fractions. The column 
was then re-equilibrated with buffer. Protein concentra-
tions were measured with BCA protein assay kit using a 
spectrophotometer. Recombinant enzymes were stored 
at −80 °C after flash freezing in liquid nitrogen.
In vitro reaction system
The reaction system was performed as previously 
described [18] to ensure the correct concentration of 
individually enzyme. For the demonstrated assay, a vari-
ety levels of each enzyme component and ATP were 
added to the reaction buffer which contain 50 mM potas-
sium phosphate, 30  mM potassium chloride, 10  mM 
magnesium chloride, and 4 mM β-mercaptoethanol. The 
reaction was initiated by addition of 2.5 mM mevalonic 
acid which was made by the saponification of mevalonol-
actone with KOH at 1.05:1 (vol:vol) KOH:mevlonolactone 
for 30 min at 37 °C, and then incubated at 30 °C for 4 h. 
To confirm isoprene had accumulated in the 2 ml reac-
tion system, 0.2 ml of the headspace gas of sealed 10 ml 
vial were analyzed by gas chromatography using Agilent 
7890B GC (Agilent, American) equipped with a flame 
ionization detector and a Agilent HP-INNWOX column, 
designed to detect short-chain hydrocarbons. Amounts 
of isoprene produced in the recombinant system were 
calculated by comparison with an isoprene standard 
(Aladdin, China).
Gas chromatography (GC) analysis of isoprene
1  ml of off-gas samples from the headspace of the fer-
mentor were analyzed as described earlier [16] using a 
GC (Agilent 7890A, America) equipped with a flame 
ionization detector (FID) and a HP-INNOWAX column 
(30  m  ×  320  μm  ×  8  μm). N2 was used as carrier gas 
with a linear velocity of 1 ml/min. The product was char-
acterized by direct comparison with standard isoprene 
(TCI-EP, Tokyo, Japan). The peak area was converted to 
isoprene concentration by comparing with a standard 
curve plotted with a set of known concentration of iso-
prene. Then isoprene accumulation was measured every 
30 min by GC.
The comparison of production of isoprene in vitro 
and in vivo
To compare isoprene production in shake flasks (in vivo) 
and in  vitro, the engineered strain E. coli BL21(DE3)/
pYJM14/pACY-ISPS (Table  1) were cultured in 500  ml 
sealed glass flasks containing 50 ml of M9 medium sup-
plemented with 10 g/L glucose and 0.5 g/L yeast extract, 
34  μg/mL chloramphenicol, and 100  μg/mL Ampicillin. 
IPTG was added to the medium when the cell density 
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OD600 reached to 0.6 and the cultures were performed at 
30  °C in rotary shaker (180  rpm). For isoprene produc-
tion, the substrate 2.5  mM mevalonate was added after 
the cell was induced and cultivated at 30 °C for 4 and 16 h 
respectively. During the cultivation, samples of both the 
flask headspace and the culture were taken at multiple 
times points.
To set up similar enzyme levels in the in vitro system 
comparing to the in vivo control. The intracellular MVK 
concentration of the in  vivo strain was firstly quanti-
fied using Quantity One Software (Biorad) described 
previously [19]. When OD600 reached 0.6, intracellu-
lar MVK concentration was about 0.4  µM. According 
to the optimized molarity ration for the in vitro system, 
0.4  µM of MVK, PMK, MVD, 0.8  µM of IDI, 6.4  µM 
of ISPS was added in the 50  ml in  vitro reaction sys-
tem. 10 mM ATP, 50 mM potassium phosphate, 30 mM 
potassium chloride, 10  mM magnesium chloride, and 
4  mM β-mercaptoethanol were also added in the reac-
tion system. The reaction was initiated by addition of 
2.5 mM mevalonic acid which was made by the saponi-
fication of mevalonolactone with KOH at 1.05:1 (vol:vol) 
KOH:mevlonolactone for 30 min at 37 °C, and then incu-
bated at 30  °C in rotary shaker (180  rpm). During the 
cultivation, samples of both the flask headspace and the 
culture were taken at multiple times points.
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